

**IN THE  
SUPREME COURT OF THE UNITED STATES**

---

No. \_\_\_\_

---

SHIRE US INC; SHIRE LLC,

*Applicants,*

v.

MARK BLACKBURN,

*Respondent.*

---

**APPLICATION TO THE HON. JUSTICE CLARENCE THOMAS  
FOR AN EXTENSION OF TIME WITHIN WHICH TO FILE  
A PETITION FOR A WRIT OF CERTIORARI TO THE  
UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT**

---

Pursuant to Supreme Court Rule 13(5), Shire US Inc and Shire LLC<sup>1</sup> (“Applicants”) hereby move for an extension of time of 30 days, up to and including May 5, 2023, for the filing of a petition for a writ of certiorari. Unless an extension is granted, the deadline for filing the petition for certiorari will be April 5, 2023.

In support of this request, Applicants state as follows:

1. The United States Court of Appeals for the Eleventh Circuit rendered its decision on November 7, 2022 (Exhibit 1) and denied a timely petition for rehearing on January 5, 2023 (Exhibit 2). This Court has jurisdiction under 28 U.S.C. §1254(1).

---

<sup>1</sup> In July 2020, Shire US Inc and Shire LLC merged into Takeda Pharmaceuticals U.S.A., Inc.

2. This case concerns whether federal law preempts a state-law failure-to-warn claim that implicates the “Highlights” section of a prescription pharmaceutical drug label. The Highlights section of a drug label contains important information for prescribing the drug safely and effectively, *see* 21 C.F.R. §201.57(a), and the FDA requires drug manufacturers to obtain agency approval before making any changes to that section, *see id.* §314.70(b)(2)(v)(C) (identifying “[a]ny change to the information required by §201.57(a)” as one of the “[c]hanges requiring supplement submission and approval prior to distribution of the product made using the change”). Accordingly, if a plaintiff brings a state-law claim asserting that a drug manufacturer had a state-law duty to independently change the Highlights section, that claim is squarely preempted. *See, e.g., PLIVA, Inc. v. Mensing*, 564 U.S. 604, 623-24 (2011) (preemption exists “when a party cannot satisfy its state duties without the Federal Government’s special permission and assistance, which is dependent on the exercise of judgment by a federal agency”).

3. Applicants manufacture Lialda, a drug indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis; in 2016 Mark Blackburn (“Respondent”) sued Applicants, alleging that he developed kidney disease after he was prescribed Lialda to treat Crohn’s disease. Ex. 1 at 2. In 2016, Respondent asserted a state-law cause of action claiming that he would not have developed kidney disease if Applicants had independently altered the Highlights section of Lialda’s label to include different warnings from those approved by the Food and Drug

Administration, and Applicants subsequently sought summary judgment on federal preemption grounds. *See* Ex. 1 at 2, 8.

4. In the decision below, the Eleventh Circuit found Respondent’s state-law failure-to-warn cause of action is not preempted. Although the court acknowledged that 21 C.F.R. §314.70(b)(2)(v)(C) “requires a supplement for ‘[a]ny change to the information required by’ the Highlights section,” it concluded that this case turns on 21 C.F.R. §314.70(b)(2)(v)(A), which “exempts” from the prior-approval requirement “[c]hanges in labeling ... described in” 21 C.F.R. §314.70(c)(6)(iii)—also known as the “changes-being-effected” regulation. Ex. 1 at 8. In the court’s view, under the changes-being-effected regulation and without obtaining prior FDA approval, Applicants could have “add[ed] or strengthen[ed] an instruction” on Lialda’s label “about dosage and administration.” Ex. 1 at 8. As the court failed to recognize, however, the changes-being-effected regulation expressly states that it does *not* apply—and thus prior FDA approval remains necessary—when changes to the Highlights section are at issue. *See* 21 C.F.R. §314.70(c)(6)(iii) (“The agency may designate a category of changes for the purpose of providing that, in the case of a change in such category, the holder of an approved NDA may commence distribution of the drug product involved upon receipt by the agency of a supplement for the change. These changes include, but are not limited to ... [c]hanges in the labeling to reflect newly acquired information, *except for changes to the information required in §201.57(a) of this chapter* [the regulation governing the Highlights section of a drug’s

label] (*which must be made under paragraph (b)(2)(v)(C) of this section* [the regulation requiring a pre-approval supplement to change a drug’s label])” (emphasis added)).

5. The Eleventh Circuit’s decision thus is plainly wrong and inconsistent with this Court’s precedent, as commentators have recognized. *See, e.g.*, James M. Beck, *Blackburn—That’s Just Plain Wrong* (Dec. 19, 2022), <https://bit.ly/3TlFWs4>. That decision, moreover, will have far-reaching consequences, as it will compel drug manufacturers to make potentially risky changes to the Highlights sections of drug labels and will expose drug manufacturers to meritless state-law claims that are clearly preempted.

6. Applicants are in the process of retaining additional Supreme Court counsel to prepare a petition for certiorari, and the newly retained counsel will need additional time to fully examine the record and research the legal issues presented in this case.

7. Applicants therefore request a modest extension to allow for the preparation of a petition that fully addresses the important and far-reaching issues raised by the decision below.

8. This application is being filed at least 10 days before the date that Applicants’ petition currently is due.

WHEREFORE, for the foregoing reasons, Applicants request that an extension of time up to and including May 5, 2023, be granted within which Applicants may file a petition for a writ of certiorari.

Respectfully submitted,



---

JEFFREY F. PECK  
ULMER & BERNE LLP  
312 Walnut Street  
Suite 1400  
Cincinnati, OH 45202  
(513) 698-5010  
jpeck@ulmer.com

*Counsel for Applicants*

March 21, 2023

**IN THE  
SUPREME COURT OF THE UNITED STATES**

\_\_\_\_\_  
No. \_\_\_\_  
\_\_\_\_\_

SHIRE US INC.; SHIRE LLC,

*Applicants,*

v.

MARK BLACKBURN,

*Respondent.*

\_\_\_\_\_  
**CERTIFICATE OF SERVICE**  
\_\_\_\_\_


I, Jeffrey F. Peck, a member of the Supreme Court Bar, hereby certify that three copies of the attached Application to Honorable Justice Clarence Thomas for an Extension of Time to File a Petition for Writ of Certiorari to the United States Court of Appeals for the Eleventh Circuit were served on:

Jonathan H. Waller  
Waller Law Office, PC  
3595 Grandview Pkwy., Ste 500  
Birmingham, AL 35243

Keith Jackson  
Robert R. Riley, Jr.  
Riley & Jackson, PC  
3530 Independence Dr.  
Birmingham, AL 35209

*Counsel for Respondent*

Service was made by first-class mail on March 21, 2023.



\_\_\_\_\_  
JEFFREY F. PECK  
ULMER & BERNE LLP  
312 Walnut Street  
Suite 1400  
Cincinnati, OH 45202  
(513) 698-5010  
jpeck@ulmer.com